Innovative approaches for demonstration of bioequivalence: the US FDA perspective

Author： Zhang Xinyuan   Zheng Nan   Lionberger Robert A   Yu Lawrence X  

Publisher： Future Science

ISSN： 2041-5990

Source： Therapeutic Delivery, Vol.4, Iss.6, 2013-06, pp. : 725-740

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bioequivalence of Highly Variable Drugs: A Comparison of the Newly Proposed Regulatory Approaches by FDA and EMA

By Karalis Vangelis   Symillides Mira   Macheras Panos  

Pharmaceutical Research, Vol. 29, Iss. 4, 2012-04 ,pp. : 1066-1077

Springer Publishing Company

Access to resources Recommend Favorite

Current regulatory approaches of bioequivalence testing

By Karalis Vangelis   Macheras Panos  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 8, 2012-08 ,pp. : 929-942

Informa Healthcare

Access to resources Recommend Favorite

US FDA news

By  

Inpharma, Vol. 1, Iss. 1231, 2000-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

US FDA news

By  

Inpharma, Vol. 1, Iss. 1239, 2000-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

Recent US FDA approvals

By  

Inpharma, Vol. 1, Iss. 1242, 2000-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite